Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Roy S. Herbst, MD, PhD, on Osimertinib for NSCLC: Clinical Implications of a Potentially Practice-Changing Finding

Posted: Friday, May 29, 2020

Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses the positive findings in the ADAURA study on osimertinib in stage IB–IIIA EGFR mutation–positive non–small cell lung cancer and the impact it will have on patients by preventing metastases and giving them an oral therapy option.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.